Aurinia Pharmaceuticals Inc

Research Aurinia Pharmaceuticals Inc (AUPH) on Bullrun: valuation model: 82.8% undervalued, market cap USD 2.16B, P/E 7.8. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAUPH
• ExchangeNASDAQ
• CountryCanada
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal82.8% undervalued
• Market capUSD 2.16B
• P/E7.8
• Financial periodFY2025
• RevenueUSD 283.06M
• Revenue growth20.4%
• Net incomeUSD 287.20M
• Gross margin88.5%

Valuation Snapshot

Bullrun's latest valuation model marks Aurinia Pharmaceuticals Inc as 82.8% undervalued; latest market cap is USD 2.16B; P/E is 7.8.

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases.

Frequently asked questions

Is Aurinia Pharmaceuticals Inc overvalued or undervalued?

Bullrun's valuation model currently marks Aurinia Pharmaceuticals Inc as 82.8% undervalued.

What is Aurinia Pharmaceuticals Inc's market cap?

Aurinia Pharmaceuticals Inc's market capitalization is USD 2.16B.

What is Aurinia Pharmaceuticals Inc's P/E ratio?

Aurinia Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 7.8.

What does Aurinia Pharmaceuticals Inc do?

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.